Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well ziv-aflibercept works in treating patients with
locally advanced, unresectable or metastatic gynecologic soft tissue sarcoma. Ziv-aflibercept
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and
by blocking blood flow to the tumor.